Clinical trials: Advanced Esophageal Cancer
Esophageal Neoplasms
Anlotinib Retrospective Study for Esophageal Cancer
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal…
- Trial name
- NCT05303740
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Feng Wang
Esophageal Cancer, GastroEsophageal Cancer
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
The purpose of this study is to collect real-world data to describe the effectiveness and tolerability of first line (1L) zanidatamab-containing therapies and describe the subsequent lines of treatment in participants with…
- Conditions
- Esophageal Cancer, GastroEsophageal Cancer, Gastroesophageal-junction Cancer, HER2-positive Gastric Cancer
- Trial name
- ZOLA (NCT07780968)
- Testing
- Zanidatamab
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Jazz Pharmaceuticals
Toxicity, Drug
Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma
Neoadjuvant chemoradiotherapy followed by surgery has been the standard modality for locally advance esophageal carcinoma. According to CROSS study, the pathological complete remission rate achieved by paclitaxel and carboplatin…
- Trial name
- NCT05355168
- Testing
- neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Anhui Provincial Hospital
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms
Evaluation of Skin Tests in Biotherapy Allergies
Biotherapies are biological (extracted from an organism or living tissue) or biotechnological drugs used in the treatment of multiple conditions, such as autoimmune inflammatory diseases, cancers, and hematologic diseases.
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Melanoma Neoplasms, Small Cell Bronchial Carcinomas, Bronchial Carcinoma
- Trial name
- ETCABIO (NCT06971848)
- Testing
- Drug skin tests (investigating hypersensitivity to a biotherapy)
- Where
- France
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Cancer
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003867
- Testing
- capecitabine, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
ESCC
DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer
To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC
- Trial name
- NCT05050760
- Testing
- Camrelizumab, DCF
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Xijing Hospital
Esophageal Squamous Cell Cancer
Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT01993784
- Testing
- nimotuzumab
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Peking University
Esophageal Neoplasms, Stomach Neoplasms
Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma
The main purpose of this study is to determine the effects of treatment with carboplatin, docetaxel and capecitabine in patients with incurable cancer of the esophagus or stomach.
- Trial name
- SEED (NCT02177552)
- Testing
- Carboplatin, Docetaxel, Capecitabine
- Where
- Denmark
- Volunteers
- 98 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Esophageal Carcinoma
Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer
The purpose of this study is to show if the adoptive cellular therapy with autologous dendritic cells and cytokine-induced killer cells (CIK) combined with concurrent chemoradiation could improve the quality of life of the…
- Trial name
- NCT01691625
- Testing
- concurrent chemoradiotherapy plus DC-CIK immunotherapy, Concurrent chemoradiation only
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Capital Medical University
Gastric Cancer, Oesophageal Carcinoma
A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer
This is a Phase 2, open-label, dose optimization/expansion study to assess the preliminary efficacy and safety of SAR445877 as a monotherapy for Chinese participants aged at least 18 years with advanced Gastric…
- Trial name
- NCT07692204
- Testing
- SAR445877
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sanofi
Esophageal Squamous Cell Carcinoma (ESCC)
Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy and safety of neoadjuvant low-dose radiotherapy combined with Retlirafusp alfa and chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07682376
- Testing
- Low-dose radiotherapy + Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin, Retlirafusp alfa + nab-paclitaxel + cisplatin/carboplatin
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Harbin Medical University
Esophageal Cancer
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
This is a randomized, controlled, multi-center, open trial, unresectable locally advanced or metastatic esophageal squamous cell carcinoma patients that failed at least second-line treatment and overexpressed EGFR were enrolled…
- Trial name
- NCT04415853
- Testing
- Lerotinib, Irinotecan/Tegafur
- Where
- China
- Volunteers
- 416 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Esophageal Neoplasms, Hepatocellular Carcinoma
A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies
To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.
- Conditions
- Esophageal Neoplasms, Hepatocellular Carcinoma, Colorectal Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00057395
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Aronex Pharmaceuticals
Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ)…
- Conditions
- Locally Advanced Gastric Adenocarcinoma, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer
- Trial name
- ZODIAC (NCT06250036)
- Testing
- Single agent zimberelimab, Combination zimberelimab + domvanalimab
- Where
- 10 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Esophageal Squamous Cell Carcinoma
Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification
The purpose of this study is to evaluate the safety and efficacy of Z650 in Advanced Esophageal Squamous Cell Carcinoma patients With EGFR Over expression or Gene Amplification.
- Trial name
- NCT03888092
- Testing
- Z650
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Esophagus Cancer, Bladder Cancer
The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1
Phase Ia: single-dose escalation study: accelerated titration combined with traditional "3+3" dose. Sample size is correlated with the DLT occurring in each dose group.
- Conditions
- Esophagus Cancer, Bladder Cancer, Liver Cancer, Ovarian Cancer
- Trial name
- NCT05829057
- Testing
- Intravenous injection of P-IL-2, P-IL-2 plus Anti-PD-1 Monoclonal Antibody
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Zhejiang University
Locally Advanced Esophageal Squamous Cell Carcinoma
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if cadonilimab combined with anlotinib can be a safe and effective neoadjuvant therapy in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06426797
- Testing
- Cadonilimab plus anlotinib
- Volunteers
- 25 people
- Sponsor
- Peking University People's Hospital
Solid Tumor, KRAS Mutation
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
This study is no longer open to new participants. It was a study in adults with advanced cancer in the stomach and oesophagus. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Trial name
- NCT06056024
- Testing
- BI 3706674
- Where
- 17 sites in United States, Japan and 2 more
- Volunteers
- 47 people
- Sponsor
- Boehringer Ingelheim
Esophageal Cancer
Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW
Radiation and chemotherapy can shrink the tumor. For certain types of cancer, immunotherapy is added to further reduce the tumor size.
- Trial name
- GLOW (NCT07196384)
- Testing
- Spectroscopy system, Nivolumab-800CW, Durvalumab-680LT
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen
Esophageal Cancer
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
Esophageal cancer is a highly aggressive tumor. Treatment options are various and range from chemotherapy to radiotherapy and several surgical techniques. Nevertheless, the overall survival rates for this disease remain poor.
- Trial name
- NCT01787006
- Testing
- Cetuximab, Cisplatin, 5-FU, Radiotherapy
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- University Hospital Schleswig-Holstein